

RATIONALE

The Italian Network for Tumor Biotherapy (NIBIT) celebrates the International Clinical Trials' Day on Biotherapy of Cancer under the auspices of ECRIN (European Clinical Research Infrastructures Network) and with the sponsorship of Alliance Against Cancer and the Istituto Superiore di Sanità.

The International Clinical Trials' Day is a traditional yearly appointment for ECRIN, dedicated to the celebration of what can be considered the first documented randomized clinical trial in the history of medicine, which was carried out in 1747 by James Lind, while serving as naval surgeon on HMS Salisbury, on 12 sailors afflicted by scurvy.

A workshop of European networks dedicated to cancer biotherapies will take place at the same venue. Networks representatives will exchange and discuss their experience.

Scientific Committee

F. Belardelli, J. Demotes-Mainard, M. Ferrantini, M. Maio, G. Parmiani

Local Organising Secretariat

**Focal Point International Affairs ACC
and Istituto Superiore di Sanità**

focalpoint.acc@istge.it

C. Lombardo, F. d'Alessandro, T. Rondanina, D. Albanese, M. Romero

BC Congressi srl

segreteria@bccongressi.it www.bccongressi.it

Ph.: +39 010 595 70 60 – Fax: +39 010 595 85 48

This event

is organised by



Alleanza contro il cancro



Istituto Superiore di Sanità



**The National Committee on Biosafety
Biotechnology and Life Science
Italian Council of Ministers**

In collaboration and
under the auspices of



and



Italian Network for Tumor Biotherapy



The Organisation of European Cancer Institutes "OECI" in connection with the 2008 General Assembly, promotes a series of collateral events as part of the

OECI 2008 Scientific Week

**Discovering new
worlds in medicine**

May 22nd, 2008

**The International Clinical Trials'
Day on Biotherapy of Cancer**

and

**Workshop of European networks
for bio-immunotherapy of tumors**

Palazzo Ducale
Sala Camino



To register: www.oeci.org

PARTICIPANTS

Giovanni Apolone

Istituto di Ricerche Farmacologiche "Mario Negri", Milan – I

Filippo Belardelli

Istituto Superiore di Sanità, Rome – I

Claudio Bordignon

MolMed, Milan - I

Roberto Camerini

Sigma-Tau, Rome – I

Giuliano d'Agnolo

The National Committee on Biosafety Biotechnology and Life Science of the Presidenza del Consiglio dei Ministri, Rome - I

Francesco De Lorenzo

F.A.V.O. – AIMaC – I

Jacques Demotes-Mainard

Institut National de la Santé et de la Recherche Médicale (INSERM), Paris – F

Louis J. Denis

Europa Uomo, Antwerp – B

Nicola Fabris

C.I.R.M. - Consorzio Italiano per la Ricerca in Medicina – I

Maria Ferrantini

Istituto Superiore di Sanità, Rome – I

Leif Hakansson

Biotherapy Development Association – D

Christoph Huber

Johannes Gutenberg-University of Mainz – D

Ingrid Kössler

Europa Donna – S

Michele Maio

University Hospital of Siena – I

Francesco M. Marincola

National Institutes of Health, Bethesda, MD - USA

Giorgio Parmiani

San Raffaele Foundation Scientific Institute, Milan – I

Enrico Proietti

Istituto Superiore di Sanità, Rome – I

Paola Queirolo

Istituto Nazionale per la Ricerca sul Cancro, Genoa – I

Thomas Wölfel

Johannes Gutenberg-University of Mainz – D

SCIENTIFIC PROGRAMME

MORNING

International Clinical Trials' Day on Biotherapy of Cancer

under the auspices of ECRIN

Chairpersons: Maria Ferrantini, Michele Maio

- 9.00** Welcome and opening address
Maria Ferrantini
- 9.10** The ECRIN programme: heading to the development of the pan-European infrastructure
Jacques Demotes-Mainard
- 9.30** The role of ISS and ACC in the promotion of the Italian participation to the ESFRI Biology and Medical Science Infrastructures
Filippo Belardelli
- 9.40** Clinical trials in oncology: for patients or for industry?
Giovanni Apolone
- 10.00** CIRM: a research consortium for education and training
Nicola Fabris
- 10.20** **COFFEE BREAK**
- 10.50** Biotherapy of cancer: reality and perspectives
Giorgio Parmiani
- 11.10** The promise of combining chemotherapy and immunotherapy
Enrico Proietti
- 11.30** The public-private partnership in the field of cancer biotherapies
Roberto Camerini
- 11.50** The Europa Donna point of view on the impact of biotherapy for the treatment of cancer patients
Ingrid Kössler
- 12.05** Clinical Trials: what cancer patients need to know
Francesco De Lorenzo
- 12.20** From Patient to Partner: Barriers to overcome in European Health Care
Louis J. Denis
- 12.40** General Discussion
- 13.00** **LUNCH**

SCIENTIFIC PROGRAMME

AFTERNOON

Workshop of European networks for bio-immunotherapy of tumors

The National Committee on Biosafety Biotechnology and Life Science kindly contributed to the organisation of this event

Chairpersons: Giorgio Parmiani, Giuliano D'Agnolo

- 14.30** NIBIT and the Italian biotherapy of tumors
Michele Maio
- 14.50** Ongoing Italian biotherapy trials: the experience of NIBIT
Paola Queirolo
- 15.10** A call for a global network of cancer biotherapy researchers
Francesco M. Marincola
- 15.30** The German network for immunotherapy of tumors
Christoph Huber
- 15.50** T-Cell responses to human melanoma are highly individual
Thomas Wölfel
- 16.10** Arenegyr (NGR-TNF): a novel tumor vasculature-targeting agent for the treatment of cancer
Claudio Bordignon
- 16.30** Cancer-Related Immunosuppression
Leif Hakansson
- 16.50** Pan-European coordination and infrastructural initiatives: an opportunity for cancer biotherapy
Maria Ferrantini
- 17.00** General Discussion
- 17.20** **Closure**